Ravulizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ravulizumab
- Ravulizumab: From Paroxysmal Nocturnal Hemoglobinuria to Autosomal Recessive Severe Congenital Neutropenia due to G6PC3 Deficiency
Ravulizumab: From Paroxysmal Nocturnal Hemoglobinuria to Autosomal Recessive Severe Congenital Neutropenia due to G6PC3 Deficiency
One-Sentence Summary
Ravulizumab is a long-acting C5 complement inhibitor, originally used to treat paroxysmal nocturnal hemoglobinuria (PNH). The TxGNN model predicts it may be effective for autosomal recessive severe congenital neutropenia due to G6PC3 deficiency, but currently there are 0 clinical trials and 0 publications supporting this direction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Paroxysmal nocturnal hemoglobinuria |
| Predicted New Indication | Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, ravulizumab is a long-acting inhibitor of complement component C5. It blocks terminal complement activity, and its efficacy in PNH, a complement-mediated hemolytic disease, is established.
For the predicted indication, the link is weak. G6PC3 deficiency is a disorder of neutrophil glucose metabolism and survival, and no complement-mediated mechanism is established. The TxGNN score is a graph-based prediction only, with no supporting clinical or literature evidence.
Other top-ranked predictions show the same pattern. These include cyclic hematopoiesis, primary hyperoxaluria, severe congenital neutropenia (and its CXCR2-deficiency and X-linked forms), primary immunodeficiency due to p14 deficiency, pseudo-von Willebrand disease, primary release disorder of platelets, and megaloblastic anemia. None has a recognised C5-inhibition rationale or any trial or publication in the data compiled for this report. For primary hyperoxaluria, complement may play a secondary role in oxalate-induced kidney injury, but this is speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17026P | ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/ML | Infusion, solution concentrate | Indication text not listed in the registration data |
Safety Considerations
- Contraindications (knowledge graph, not label text): Meningococcal infection. Terminal complement blockade raises the risk of serious meningococcal infection, which is especially relevant in immunodeficient populations such as p14 deficiency.
- Drug Interactions: Four minor interactions were identified, all with human immunoglobulin G products (intravenous, subcutaneous, intramuscular, and intravenous/subcutaneous).
Please refer to the package insert for further safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (Evidence Level L5). There are no clinical trials or publications, and no plausible C5-related mechanism for G6PC3 deficiency. Ravulizumab also carries a meningococcal infection risk.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications for the Singapore-registered product
- Evidence that complement activation contributes to the pathology of G6PC3 deficiency (preclinical or mechanistic studies)
- A literature and trial search specific to the predicted indication
- A safety plan for infection risk (such as meningococcal vaccination and monitoring) in neutropenic or immunodeficient patients
- Assessment of route compatibility (ravulizumab is available only as an intravenous infusion in Singapore)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.